Attached files

file filename
EX-99.1 - PRESS RELEASE - ACURA PHARMACEUTICALS, INCv237348_ex99-1.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
 


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act Of 1934

October 17, 2011
Date of Report (Date of earliest event reported)
 


ACURA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
 


State of New York
 
1-10113
 
11-0853640
(State of Other Jurisdiction
 
(Commission File Number)
 
(I.R.S. Employer
of Incorporation)
     
Identification Number)

616 N. North Court, Suite 120
 Palatine, Illinois 60067
(Address of principal executive offices) (Zip Code)

(847) 705-7709
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

 
 

 

Item 8.01
Other Events

On October 17, 2011 we issued a press release announcing that Pfizer, Inc. (Pfizer) has unformed us that it has commenced executing its commercialization plan for OXECTA®(oxycodone HCl, USP) Tablets CII in the United States.  A copy of our press release is being furnished as Exhibit 99.1 hereto.

Item 9.01
Financial Statements and Exhibits

Exhibit Number
 
Description
     
99.1
 
Press Release dated October 17, 2011

 
 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

  ACURA PHARMACEUTICALS, INC.
     
 
By:
/s/ Peter A. Clemens
   
Peter A. Clemens
   
Senior Vice President & Chief Financial Officer

Date:  October 17, 2011

 
 

 
 
Exhibit Index
 
Exhibit Number
 
Description
     
99.1
  
Press Release dated October 17, 2011